Unification of favourable intermediate‐, unfavourable intermediate‐, and very high‐risk stratification criteria for prostate cancer
- 3 June 2017
- journal article
- Published by Wiley in BJU International
- Vol. 120 (5B) , E87-E95
Abstract
Objective: To improve on the existing risk‐stratification systems for prostate cancer. Patients and Methods: This was a retrospective investigation including 2 248 patients undergoing dose‐escalated external beam radiotherapy ( EBRT ) at a single institution. We separated National Comprehensive Cancer Network ( NCCN ) intermediate‐risk prostate cancer into ‘favourable’ and ‘unfavourable’ groups based on primary Gleason pattern, percentage of positive biopsy cores ( PPBC ), and number of NCCN intermediate‐risk factors. Similarly, NCCN high‐risk prostate cancer was stratified into ‘standard’ and ‘very high‐risk’ groups based on primary Gleason pattern, PPBC , number of NCCN high‐risk factors, and stage T3b–T4 disease. Patients with unfavourable‐intermediate‐risk ( UIR ) prostate cancer had significantly inferior prostate‐specific antigen relapse‐free survival ( PSA ‐ RFS , P < 0.001), distant metastasis‐free survival ( DMFS , P < 0.001), prostate cancer‐specific mortality ( PCSM , P < 0.001), and overall survival ( OS , P < 0.001) compared with patients with favourable‐intermediate‐risk ( FIR ) prostate cancer. Similarly, patients with very high‐risk ( VHR ) prostate cancer had significantly worse PSA ‐ RFS ( P < 0.001), DMFS ( P < 0.001), and PCSM ( P = 0.001) compared with patients with standard high‐risk ( SHR ) prostate cancer. Moreover, patients with FIR and low‐risk prostate cancer had similar outcomes, as did patients with UIR and SHR prostate cancer. Results: Consequently, we propose the following risk‐stratification system: Group 1, low risk and FIR ; Group 2, UIR and SHR ; and Group 3, VHR . These groups have markedly different outcomes, with 8‐year distant metastasis rates of 3%, 9%, and 29% ( P < 0.001) for Groups 1, 2, and 3, respectively, and 8‐year PCSM of 1%, 4%, and 13% ( P < 0.001) after EBRT . This modified stratification system was significantly more accurate than the three‐tiered NCCN system currently in clinical use for all outcomes. Conclusion: Modifying the NCCN risk‐stratification system to group FIR with low‐risk patients and UIR with SHR patients, results in modestly improved prediction of outcomes, potentially allowing better personalisation of therapeutic recommendations.Keywords
This publication has 27 references indexed in Scilit:
- Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate CancerJournal of Clinical Oncology, 2015
- Aggressive Variants of Castration-Resistant Prostate CancerClinical Cancer Research, 2014
- Prostate Cancer, Version 2.2014Journal of the National Comprehensive Cancer Network, 2014
- A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation TherapyEuropean Urology, 2013
- Very-high-risk localized prostate cancer: definition and outcomesProstate Cancer and Prostatic Diseases, 2013
- Contemporary Evaluation of the National Comprehensive Cancer Network Prostate Cancer Risk Classification SystemUrology, 2012
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?The Lancet Oncology, 2012
- Gleason Pattern 5 Is the Greatest Risk Factor for Clinical Failure and Death From Prostate Cancer After Dose-Escalated Radiation Therapy and Hormonal AblationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Impact of the Percentage of Positive Prostate Cores on Prostate Cancer–Specific Mortality for Patients With Low or Favorable Intermediate-Risk DiseaseJournal of Clinical Oncology, 2004